Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
Possible pediatric nephrotoxicity of cisplatin
- At: 2018 FIP Congress in Glasgow (Scotland)
- Type: Poster
- By: ABDELRAHMAN, Sarah (Children's Cancer Hospital Egypt, Department of Pharmaceutical Services & Sciences)
- Co-author(s): Sarah Mohamed Abdelrahman
Hala Zaki: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt
Alaa Al Haddad: Department of Pediatric Oncology & Stem Cell Transplant, Children's Cancer Hospital , Cairo, Egypt
Helmy Moawad: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt
BackgroundRisk of Cisplatin (CDDP) nephrotoxicity, increases with increased cumulative dose, bolus dosage and associated nephrotoxic drugs. Early detection & management improves patient care.
Methods51 patients scheduled to receive CDDP-based chemotherapy were recruited and scored for nephrotoxic events throughout chemotherapy course, then.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.
Last update 4 October 2019